Epitalon vs MOTS-c
Both Epitalon and MOTS-c are used for longevity. Here's how their evidence, dosing, and regulatory status actually compare.
Epitalon
Evidence C+Epitalon (Epithalon, AEDG)
A synthetic tetrapeptide that reportedly upregulates telomerase activity. Russian longevity studies suggest mortality reductions but Western RCTs are absent.
View full Epitalon profile →MOTS-c
Evidence BMitochondrial-derived peptide MOTS-c
A 16-amino-acid mitochondrial-derived peptide that improves insulin sensitivity and exercise capacity in animal models. Among the most promising 'mitokines' for metabolic aging.
View full MOTS-c profile →Side-by-Side
| Attribute | Epitalon | MOTS-c |
|---|---|---|
| Evidence Grade | C+ | B |
| FDA Status | Not FDA-approved — Russian-origin research peptide | Not FDA-approved — research peptide; multiple early-phase clinical trials |
| Typical Dose | 5–10 mg daily for 10–20 days, cycled (subcutaneous) | 5–10 mg, 2–3 times weekly (subcutaneous) |
| Clinics Indexed | 47 | 22 |
| Categories | anti-aging, longevity | metabolic, longevity |
Key reported benefits — Epitalon
- ✓Telomerase upregulation (preclinical)
- ✓Sleep/circadian normalization
- ✓Anti-aging signals
Key reported benefits — MOTS-c
- ✓Insulin sensitivity
- ✓Exercise capacity
- ✓Metabolic flexibility
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.